Cargando…
Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)
INTRODUCTION: Coronavirus disease 2019 (COVID-19) causes a hypercoagulable state. Several autopsy studies have found microthrombi in pulmonary circulation. METHODS: In this randomized, open-label, phase II study, we randomized COVID-19 patients requiring mechanical ventilation to receive either ther...
Autores principales: | Lemos, Anna Cristina Bertoldi, do Espírito Santo, Douglas Alexandre, Salvetti, Maísa Cabetti, Gilio, Renato Noffs, Agra, Lucas Barbosa, Pazin-Filho, Antonio, Miranda, Carlos Henrique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503069/ https://www.ncbi.nlm.nih.gov/pubmed/32977137 http://dx.doi.org/10.1016/j.thromres.2020.09.026 |
Ejemplares similares
-
Therapeutic anticoagulation in COVID-19 patients
por: Lemos, Anna Cristina Bertoldi, et al.
Publicado: (2021) -
Prophylactic and Therapeutic Effects of Oleuropein on Reperfusion-Induced Arrhythmia in Anesthetized Rat
por: Baharvand, Babak, et al.
Publicado: (2016) -
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies
por: Bikdeli, Behnood, et al.
Publicado: (2020) -
Cheminformatics-Based Anticoagulant Study of Traditionally Used Medicinal Plants
por: Pour, Mahdi Alikhani, et al.
Publicado: (2017) -
Anticoagulation and bleeding risk in patients with COVID-19
por: Musoke, Nancy, et al.
Publicado: (2020)